R 82150 | CAS#126320-77-2 | antiviral

MedKoo Cat#: 461098 | Name: R 82150

Description:

WARNING: This product is for research use only, not for human or veterinary use.

R 82150 is an antiviral drug and a member of the tetrahydroimidazo[4,5,1-jk]-[1,4]-benzodiazepin-2(1H)-thione family of compound.

Chemical Structure

R 82150

CAS#126320-77-2

Theoretical Analysis

MedKoo Cat#: 461098

Name: R 82150

CAS#: 126320-77-2

Chemical Formula: C16H21N3S

Exact Mass: 287.1456

Molecular Weight: 287.42

Elemental Analysis: C, 66.86; H, 7.36; N, 14.62; S, 11.15

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

R 82150; R-82150; R82150;

IUPAC/Chemical Name

(S)-8-methyl-7-(3-methylbut-2-en-1-yl)-6,7,8,9-tetrahydro-2,7,9a-triazabenzo[cd]azulene-1(2H)-thione

InChi Key

WTTIBCHOELPGFK-LBPRGKRZSA-N

InChi Code

InChI=1S/C16H21N3S/c1-11(2)7-8-18-10-13-5-4-6-14-15(13)19(9-12(18)3)16(20)17-14/h4-7,12H,8-10H2,1-3H3,(H,17,20)/t12-/m0/s1

SMILES Code

C/C(C)=C\CN1[C@@H](C)Cn2c3c(cccc3C1)[nH]c2=S

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 287.42 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Balzarini J, Pérez-Pérez MJ, San-Félix A, Camarasa MJ, Bathurst IC, Barr PJ, De Clercq E. Kinetics of inhibition of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase by the novel HIV-1-specific nucleoside analogue [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5 "- (4"-amino-1",2"-oxathiole-2",2"-dioxide)thymine (TSAO-T). J Biol Chem. 1992 Jun 15;267(17):11831-8. PubMed PMID: 1376314. 2: Debyser Z, Vandamme AM, Pauwels R, Baba M, Desmyter J, De Clercq E. Kinetics of inhibition of endogenous human immunodeficiency virus type 1 reverse transcription by 2',3'-dideoxynucleoside 5'-triphosphate, tetrahydroimidazo-[4,5,1-jk][1,4]-benzodiazepin-2(1H)-thion e, and 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives. J Biol Chem. 1992 Jun 15;267(17):11769-76. PubMed PMID: 1376311. 3: Debyser Z, Pauwels R, Andries K, De Clercq E. Specific HIV-1 reverse transcriptase inhibitors. J Enzyme Inhib. 1992;6(1):47-53. Review. PubMed PMID: 1285302. 4: Frank KB, Noll GJ, Connell EV, Sim IS. Kinetic interaction of human immunodeficiency virus type 1 reverse transcriptase with the antiviral tetrahydroimidazo[4,5,1-jk]-[1,4]-benzodiazepine-2-(1H)-thione compound, R82150. J Biol Chem. 1991 Aug 5;266(22):14232-6. PubMed PMID: 1713579. 5: Busso M, Resnick L. Development of an assay that detects transcriptionally competent human immunodeficiency virus type one particles. J Virol Methods. 1994 Apr;47(1-2):129-39. PubMed PMID: 7519626. 6: Pauwels R, Andries K, Desmyter J, Schols D, Kukla MJ, Breslin HJ, Raeymaeckers A, Van Gelder J, Woestenborghs R, Heykants J, et al. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature. 1990 Feb 1;343(6257):470-4. PubMed PMID: 1689015. 7: Two more attacks on HIV. Lancet. 1990 Feb 10;335(8685):345. PubMed PMID: 1967781. 8: Debyser Z, Pauwels R, Andries K, Desmyter J, Engelborghs Y, Janssen PA, De Clercq E. Allosteric inhibition of human immunodeficiency virus type 1 reverse transcriptase by tetrahydroimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one and -thione compounds. Mol Pharmacol. 1992 Jan;41(1):203-8. PubMed PMID: 1370707. 9: Debyser Z, Pauwels R, Baba M, Desmyter J, De Clercq E. Common features in the interaction of tetrahydroimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one and -thione and 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives with the human immunodeficiency virus type 1 reverse transcriptase. Mol Pharmacol. 1992 May;41(5):963-8. PubMed PMID: 1375320. 10: Jonckheere H, De Vreese K, Debyser Z, Vandekerckhove J, Balzarini J, Desmyter J, De Clercq E, Anné J. A two plasmid co-expression system in Escherichia coli for the production of virion-like reverse transcriptase of the human immunodeficiency virus type 1. J Virol Methods. 1996 Sep;61(1-2):113-25. PubMed PMID: 8882944. 11: Kleim JP, Bender R, Kirsch R, Meichsner C, Paessens A, Riess G. Mutational analysis of residue 190 of human immunodeficiency virus type 1 reverse transcriptase. Virology. 1994 May 1;200(2):696-701. PubMed PMID: 7513921. 12: Debyser Z, Pauwels R, Andries K, Desmyter J, Kukla M, Janssen PA, De Clercq E. An antiviral target on reverse transcriptase of human immunodeficiency virus type 1 revealed by tetrahydroimidazo-[4,5,1-jk] [1,4]benzodiazepin-2 (1H)-one and -thione derivatives. Proc Natl Acad Sci U S A. 1991 Feb 15;88(4):1451-5. PubMed PMID: 1705038; PubMed Central PMCID: PMC51036. 13: Vandamme AM, Debyser Z, Pauwels R, De Vreese K, Goubau P, Youle M, Gazzard B, Stoffels PA, Cauwenbergh GF, Anne J, et al. Characterization of HIV-1 strains isolated from patients treated with TIBO R82913. AIDS Res Hum Retroviruses. 1994 Jan;10(1):39-46. PubMed PMID: 7514016. 14: Mellors JW, Dutschman GE, Im GJ, Tramontano E, Winkler SR, Cheng YC. In vitro selection and molecular characterization of human immunodeficiency virus-1 resistant to non-nucleoside inhibitors of reverse transcriptase. Mol Pharmacol. 1992 Mar;41(3):446-51. Erratum in: Mol Pharmacol 1992 Jul;42(1):174. PubMed PMID: 1372083. 15: Yang G, Song Q, Charles M, Drosopoulos WC, Arnold E, Prasad VR. Use of chimeric human immunodeficiency virus types 1 and 2 reverse transcriptases for structure-function analysis and for mapping susceptibility to nonnucleoside inhibitors. J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Apr 1;11(4):326-33. PubMed PMID: 8601218. 16: Mellors JW, Im GJ, Tramontano E, Winkler SR, Medina DJ, Dutschman GE, Bazmi HZ, Piras G, Gonzalez CJ, Cheng YC. A single conservative amino acid substitution in the reverse transcriptase of human immunodeficiency virus-1 confers resistance to (+)-(5S)-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl)imidazo[4,5, 1- jk][1,4]benzodiazepin-2(1H)-thione (TIBO R82150). Mol Pharmacol. 1993 Jan;43(1):11-6. PubMed PMID: 7678690. 17: Jonckheere H, Taymans JM, Balzarini J, Velázquez S, Camarasa MJ, Desmyter J, De Clercq E, Anné J. Resistance of HIV-1 reverse transcriptase against [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro-5''-(4''-amino-1'',2''- oxathiole-2'',2''-dioxide)] (TSAO) derivatives is determined by the mutation Glu138-->Lys on the p51 subunit. J Biol Chem. 1994 Oct 14;269(41):25255-8. PubMed PMID: 7523383.